Headquarters: Osaka, Japan
Type: Biotechnology Company
Founded: 2015
Focus: Innovative therapeutics for neurological disorders
Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurological and neurodegenerative diseases. The company leverages Japan's world-class academic research to advance innovative drug candidates from discovery through clinical development.
Tree Pharmaceutical was founded with the mission of translating cutting-edge neuroscience research into effective therapies for patients suffering from devastating neurological diseases. The company focuses on unmet medical needs in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions where current treatment options are limited.
¶ Research and Development Focus
Tree Pharmaceutical has established a comprehensive Alzheimer's disease research program targeting multiple pathological mechanisms:
TP-001: Amyloid-Targeting Antibody
- Mechanism: Monoclonal antibody targeting amyloid-beta plaques
- Stage: Preclinical development
- Approach: Disease-modifying therapy targeting the core pathology of Alzheimer's disease
The company is developing antibodies that can not only prevent amyloid-beta accumulation but also promote clearance of existing plaques. This approach differentiates Tree's program from purely preventive therapies.
TP-002: Tau Pathology Modulator
- Mechanism: Small molecule inhibitor of tau phosphorylation and aggregation
- Stage: Lead optimization
- Focus: Targeting neurofibrillary tangles, the second major pathological hallmark of Alzheimer's disease
TP-003: Alpha-Synuclein Aggregation Inhibitor
- Mechanism: Small molecule targeting alpha-synuclein oligomerization
- Stage: Discovery
- Indication: Parkinson's disease with potential extension to Lewy body dementia
Tree Pharmaceutical's Parkinson's program focuses on preventing the toxic oligomerization of alpha-synuclein, which is believed to be the primary driver of dopaminergic neuron loss in Parkinson's disease.
Beyond disease-specific programs, Tree Pharmaceutical is developing a neuroprotection platform with broad applicability:
- Mitochondrial protectors: Compounds that preserve mitochondrial function in stressed neurons
- Oxidative stress inhibitors: Antioxidant therapies for neuroprotection
- Anti-inflammatory agents: Targeting neuroinflammation as a common pathway in neurodegeneration
¶ Antibody Discovery
Tree Pharmaceutical employs advanced antibody discovery technologies:
- Phage display libraries: For identifying high-affinity antibodies against disease targets
- Humanized antibody platforms: For developing therapeutic antibodies with optimal properties
- Bispecific antibody technology: For targeting multiple pathological mechanisms simultaneously
The company's medicinal chemistry team uses modern approaches:
- Structure-based drug design: Using cryo-EM and X-ray crystallography for target validation
- Computational chemistry: AI-assisted compound design and optimization
- Novel scaffold identification: Exploring chemical space beyond traditional CNS drug-like molecules
Tree Pharmaceutical validates programs using relevant disease models:
- iPSC-derived neurons: Patient-specific models for translational research
- Transgenic mouse models: For in vivo efficacy and pharmacokinetic studies
- Biomarker development: Identifying patient selection biomarkers and treatment response indicators
Tree Pharmaceutical maintains strong collaborations with leading Japanese universities:
The company has a strategic partnership with Osaka University, one of Japan's leading research institutions in neuroscience:
- Joint research programs on Alzheimer's disease mechanisms
- Access to state-of-the-art research facilities
- Talent pipeline for research and development positions
Collaboration with Kyoto University provides access to:
- Advanced stem cell research capabilities
- Novel drug target identification
- Expertise in protein aggregation mechanisms
Partnership for natural product-based drug discovery and medicinal chemistry optimization.
| Program |
Indication |
Mechanism |
Development Stage |
| TP-001 |
Alzheimer's disease |
Amyloid-beta antibody |
Preclinical |
| TP-002 |
Alzheimer's disease |
Tau modulator |
Lead optimization |
| TP-003 |
Parkinson's disease |
Alpha-synuclein inhibitor |
Discovery |
| TP-004 |
Neuroprotection |
Mitochondrial protector |
Discovery |
Tree Pharmaceutical pursues a phased development approach:
- Early-stage development: Advance programs through preclinical validation with academic partners
- Clinical proof-of-concept: Partner with larger pharmaceutical companies for clinical development
- Global commercialization: Leverage pharmaceutical partnerships for international markets
The company is actively seeking pharmaceutical partnerships for:
- Co-development agreements: For advancing clinical programs
- Licensing deals: For regional or global commercialization rights
- Acquisition opportunities: For companies seeking to expand their neuroscience pipeline
¶ Funding and Investment
Tree Pharmaceutical has attracted investment from Japanese venture capital firms focused on biotechnology:
- Series A (2016): Initial funding for establishing research operations
- Series B (2019): Funding for pipeline expansion and lead program advancement
- Strategic investment (2022): From pharmaceutical partner for specific program development
¶ Team and Leadership
Tree Pharmaceutical brings together experienced drug developers:
- Scientific founders: Academic researchers from Osaka University with expertise in neurodegenerative disease mechanisms
- Management team: Industry veterans from major Japanese pharmaceutical companies with track records in drug development
- Advisory board: Leading neuroscientists from Japanese and international institutions
Tree Pharmaceutical aims to become a leading Japanese biotech company in neurology:
- Advance lead program to IND: TP-001 targeting Alzheimer's disease
- Expand pipeline: Additional programs in Parkinson's disease and rare neurological conditions
- Build clinical capabilities: Establish clinical development expertise
- International partnerships: Expand beyond Japan for global development